Twist Bioscience to Present at UBS Genomics 2.0 and Medtech Innovations Summit

August 1, 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 1, 2022-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Jim Thorburn, CFO of Twist Bioscience, and Patrick Finn, Ph.D., CCO of Twist Bioscience, will host a fireside chat and one-on-one meetings at the UBS Genomics 2.0 and Medtech Innovations Summit on Tuesday, August 9th, at 2:00 p.m. Pacific Time in Dana Point, California.

The presentation will be webcast live and can be accessed by visiting the “Investor Calendar” page of the investor relations section of the company's website here. A replay of the presentation will be archived for a period of 30 days following the conclusion of the live events.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20220801005103/en/

Angela Bitting
SVP, Corporate Affairs
925-202-6211
media@twistbioscience.com

Source: Twist Bioscience Corporation